Trial · NCT07904962
Different Aerobic-to-Resistance Training Ratios in Adults Aged 50 Years and Older With Prediabetes
NCT07904962, Not applicable, Not yet recruiting, China Institute of Sport Science
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Different Aerobic-to-Resistance Training Ratios in Adults Aged 50 Years and Older With Prediabetes. Trials, record NCT07904962. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904962
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Different Aerobic-to-Resistance Training Ratios in Adults Aged 50 Years and Older With Prediabetes
- NCT number
- NCT07904962
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 212 participants, estimated
- Lead sponsor
- China Institute of Sport Science
- Conditions
- Prediabetes
- Interventions
- Combined Aerobic and Resistance Training (3:1), Combined Aerobic and Resistance Training (1:1), Combined Aerobic and Resistance Training (1:3), Standardized Health Education
- First posted
- 2026-10-29
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Glycated Hemoglobin (HbA1c) at Week 12 | Week 12 | Glycated Hemoglobin (HbA1c) will be measured from a venous blood sample and reported as a percentage (%). The primary comparison will evaluate HbA1c at Week 12 between the randomized groups, with baseline HbA1c accounted for in the primary statistical analysis. |
| Secondary | Fasting Plasma Glucose at Week 12 | Week 12 | Fasting plasma glucose will be measured from a venous blood sample after an overnight fast and reported in mmol/L. |
| Secondary | 2-Hour Plasma Glucose During the Oral Glucose Tolerance Test at Week 12 | Week 12 | Plasma glucose will be measured 120 minutes after ingestion of a 75-g oral glucose load and reported in mmol/L. |
| Secondary | Normal Glucose Regulation at Week 12 | Week 12 | Normal glucose regulation will be defined as meeting all of the following criteria at Week 12: fasting plasma glucose \<5.6 mmol/L, 2-hour plasma glucose \<7.8 mmol/L during a 75-g oral glucose tolerance test, and glycated hemoglobin (HbA1c) \<5.7%. The outcome will be reported as the number and proportion of participants meeting these criteria. |
| Secondary | Total Body Fat Percentage at Week 12 | Week 12 | Total body fat percentage will be assessed using dual-energy X-ray absorptiometry (DXA) and reported as a percentage (%). |
| Secondary | Short Physical Performance Battery Total Score at Week 12 | Week 12 | Physical performance will be assessed using the Short Physical Performance Battery (SPPB), which includes standing balance, usual 4-meter walking speed, and five repeated chair stands. The total score ranges from 0 to 12 points, with higher scores indicating better physical performance. |
| Other | Matsuda Insulin Sensitivity Index at Week 12 | Week 12 | The Matsuda insulin sensitivity index will be calculated from glucose and insulin concentrations measured during the 75-g oral glucose tolerance test at 0, 30, 60, 90, and 120 minutes. Higher values indicate greater insulin sensitivity. |
| Other | Glucose Coefficient of Variation From Continuous Glucose Monitoring at Week 12 | 14-day monitoring period at Week 12 | Glucose variability will be assessed using the coefficient of variation derived from continuous glucose monitoring data. Continuous glucose monitoring will be conducted in a prespecified exploratory subgroup. |
| Other | Moderate-to-Vigorous Physical Activity at Week 12 | 7-day monitoring period at Week 12 | Moderate-to-vigorous physical activity will be assessed objectively using an ActiGraph GT3X accelerometer and summarized as average minutes per day during valid wear days. |
| Other | Knee Extensor Peak Torque at Week 12 | Week 12 | Knee extensor strength will be assessed using isokinetic dynamometry at 60°/s. Peak torque will be recorded in N·m, with bilateral measurements obtained according to the standardized testing protocol. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904962
GET https://conductscience.org/api/trials/v1/NCT07904962/registered